Literature DB >> 31479741

Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion.

S A M Dhaese1, P Colin2, H Willems3, A Heffernan4, B Gadeyne3, S Van Vooren5, P Depuydt3, E Hoste3, V Stove6, A G Verstraete6, J Lipman7, J A Roberts8, J J De Waele3.   

Abstract

The study aimed to evaluate saturation of piperacillin elimination in critically ill adult patients. Seventeen critically ill adult patients received continuous and intermittent infusion of piperacillin/tazobactam. Piperacillin plasma concentrations (n = 217) were analysed using population pharmacokinetic (PopPK) modelling. Post-hoc simulations were performed to evaluate the type I error rate associated with the study. Unseen data were used to validate the final model. The mean error (ME) and root mean square error (RMSE) were calculated as a measure of bias and imprecision, respectively. A PopPK model with parallel linear and non-linear elimination best fitted the data. The median and 95% confidence interval (CI) for the model parameters drug clearance (CL), volume of central compartment (V), volume of peripheral compartment (Vp) and intercompartmental clearance (Q) were 9 (7.69-11) L/h, 6.18 (4.93-11.2) L, 11.17 (7.26-12) L and 15.61 (12.66-23.8) L/h, respectively. The Michaelis-Menten constant (Km) and the maximum elimination rate for Michaelis-Menten elimination (Vmax) were estimated without population variability in the model to avoid overfitting and inflation of the type I error rate. The population estimates for Km and Vmax were 37.09 mg/L and 353.57 mg/h, respectively. The bias (ME) was -20.8 (95% CI -26.2 to -15.4) mg/L, whilst imprecision (RMSE) was 49.2 (95% CI 41.2-56) mg/L. In conclusion, piperacillin elimination is (partially) saturable. Moreover, the population estimate for Km lies within the therapeutic window and therefore saturation of elimination should be accounted for when defining optimum dosing regimens for piperacillin in critically ill patients.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Critically ill; Pharmacokinetics; Piperacillin; Saturation

Mesh:

Substances:

Year:  2019        PMID: 31479741     DOI: 10.1016/j.ijantimicag.2019.08.024

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

1.  Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation.

Authors:  Cristina Sanches; Geisa C S Alves; Andras Farkas; Samuel Dutra da Silva; Whocely Victor de Castro; Farah Maria Drummond Chequer; Francisco Beraldi-Magalhães; Igor Rafael Dos Santos Magalhães; André de Oliveira Baldoni; Mark D Chatfield; Jeffrey Lipman; Jason A Roberts; Suzanne L Parker
Journal:  Antibiotics (Basel)       Date:  2022-03-24

2.  Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment.

Authors:  Vibeke Klastrup; Anders Thorsted; Merete Storgaard; Steffen Christensen; Lena E Friberg; Kristina Öbrink-Hansen
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  Estimation of cefepime, piperacillin, and tazobactam clearance with iohexol-based glomerular filtration rate in paediatric patients.

Authors:  Hiie Soeorg; Aveli Noortoots; Maarja Karu; Kadri Saks; Jana Lass; Irja Lutsar; Lenne-Triin Kõrgvee
Journal:  Eur J Clin Pharmacol       Date:  2022-03-11       Impact factor: 2.953

4.  Development and evaluation of uncertainty quantifying machine learning models to predict piperacillin plasma concentrations in critically ill patients.

Authors:  Jarne Verhaeghe; Sofie A M Dhaese; Thomas De Corte; David Vander Mijnsbrugge; Heleen Aardema; Jan G Zijlstra; Alain G Verstraete; Veronique Stove; Pieter Colin; Femke Ongenae; Jan J De Waele; Sofie Van Hoecke
Journal:  BMC Med Inform Decis Mak       Date:  2022-08-25       Impact factor: 3.298

5.  Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever.

Authors:  Sabine F Maarbjerg; Anders Thorsted; Lena E Friberg; Elisabet I Nielsen; Mikala Wang; Henrik Schrøder; Birgitte K Albertsen
Journal:  Cancer Rep (Hoboken)       Date:  2021-11-18

6.  Personalized Antibiotic Therapy for the Critically Ill: Implementation Strategies and Effects on Clinical Outcome of Piperacillin Therapeutic Drug Monitoring-A Descriptive Retrospective Analysis.

Authors:  Schrader Nikolas; Riese Thorsten; Kurlbaum Max; Meybohm Patrick; Kredel Markus; Surat Güzin; Scherf-Clavel Oliver; Strate Alexander; Pospiech Andreas; Hoppe Kerstin
Journal:  Antibiotics (Basel)       Date:  2021-11-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.